产品中心

XL184



 
类型: 医药系列
编号: P002
CAS No.: 849217-68-1
NAME.: Cabozantinib
含量(%): 97
介绍:

XL184 (Cabozantinib) is a small molecule inhibitor of the tyrosine kinases c-Met and VEGFR2, and has been shown to reduce tumor growth, metastasis, and angiogenesis. It was developed by Exelixis Inc. Cabozantinib was granted orphan-drug status by the U.S. Food and Drug Administration (FDA) in January 2011. Cabozantinib was approved by the U.S. FDA in November 2012 for the treatment of medullary thyroid cancer and it is currently undergoing clinical trials for the treatment of prostate, ovarian, brain, melanoma, breast, non-small cell lung, hepatocellular and kidney cancers. (The product is for research purpose only.) (source: http://en.wikipedia.org/wiki/Cabozantinib).